Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823199 | 0.76 | — | — | |
| Morpholine SCHEMBL11126601 | 0.75 | MEN1 (0.35) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL28583405 | 0.73 | — | — | |
| Morpholine SCHEMBL8213158 | 0.70 | MEN1 (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL3056332 | 0.70 | MEN1 (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL27685879 | 0.69 | MEN1 (0.65) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL27799126 | 0.69 | MEN1 (0.65) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL3277059 | 0.68 | — | — | |
| Morpholine SCHEMBL3203810 | 0.68 | — | — | |
| Morpholine SCHEMBL199473 | 0.68 | MEN1 (0.85) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | disclosed |
| US-RE39324-E1 | Pyrimidine derivatives and oligonucleotides containing same | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6951931-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | disclosed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | IONIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-0719272-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2003-04-17 | — | — | US | disclosed |
| US-6414127-B1 | INCREASED AFFINITY TO COMPLEMENTARY OLIGONUCLEOTIDES; DNA SEQUENCING; MEDICAL DIAGNOSIS; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6028183-A | Pyrimidine derivatives and oligonucleotides containing same | GILEAD SCIENCES, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6007992-A | MIXING DERIVATIVE WITH A SAMPLE CONTAINING TARGET NUCLEIC ACIDS, AND INCUBATING FORMING A COMPLEX; FOR DIAGNOSTIC ASSAYS AND TO ENHANCE BINDING TO COMPLEMENTARY BASES | GILEAD SCIENCES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-6005096-A | FOR OLIGONUCLEOTIDES THAT ARE MODIFIED TO ENHANCE THE BINDING AFFINITY AND TO BEAR DETECTABLE LABELS; FOR DIAGNOSTIC USE | GILEAD SCIENCES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0719272-A1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995007918-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | MEN1 2281/4885KMT2A 2645/4885KDM4E 2821/4885 |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | MEN1 2281/4885KMT2A 2645/4885KDM4E 2821/4885 |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | HNRNPH3, NSUN2, HNRNPH1 | MEN1 3864/4885KMT2A 2573/4885KDM4E 3597/4885 |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | RBBP4, DDB1, DPYD | MEN1 2259/4885KMT2A 2500/4885KDM4E 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.